Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBITDA (2020 - 2026)

GeneDx Holdings has reported EBITDA over the past 7 years, most recently at -$63.6 million for Q1 2026.

  • Quarterly EBITDA fell 884.96% to -$63.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$78.0 million through Mar 2026, down 105.55% year-over-year, with the annual reading at -$20.9 million for FY2025, 59.69% up from the prior year.
  • EBITDA was -$63.6 million for Q1 2026 at GeneDx Holdings, down from -$17.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $10.7 million in Q2 2025 and troughed at -$308.8 million in Q4 2022.
  • The 5-year median for EBITDA is -$29.0 million (2024), against an average of -$50.6 million.
  • Year-over-year, EBITDA surged 136.95% in 2025 and then tumbled 884.96% in 2026.
  • A 5-year view of EBITDA shows it stood at -$308.8 million in 2022, then soared by 91.79% to -$25.3 million in 2023, then soared by 121.11% to $5.4 million in 2024, then crashed by 431.44% to -$17.7 million in 2025, then tumbled by 258.5% to -$63.6 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's EBITDA are -$63.6 million (Q1 2026), -$17.7 million (Q4 2025), and -$7.4 million (Q3 2025).